Dimerix Secures A$34 Million Non-Dilutive Funding Facility
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Dimerix plans to initially draw down only half of the committed amount, ensuring financial flexibility while minimizing costs and dilution. The company has established this facility with a syndicate of lenders from Australia and the U.S., reflecting growing confidence in its clinical programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Dimerix
- Appendix 4E and 2026 Annual Report
- Dimerix Receives US$10M Upfront Payment from Everest
- Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
- Dimerix Presents at Bioshares Summit 2026
- US Patent Granted for Dimerix New Asset DMX-652
Later from Dimerix
- Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
- S&P DJI Announces September 2026 Quarterly Rebalance
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
- First Patient Reaches Four Years in DMX-200 Clinical Program
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix